Search clinical trials for: Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor

Total 958 results

Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC

Neoadjuvant Therapy | Locally Advanced Head and Neck Squamous Cell Carcinoma

China
XIANG YANQUN

Recruiting

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | T2-3N0 or T1-2N1 | EBV-DNA≤4000 Copy/ml

China
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Changzhou Cancer Hospital of Soochow University

Completed

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (EASE)

Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

Non-Small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Carotid Artery Plaque | Plaque, Atherosclerotic | Immune Checkpoint Inhibitors | Programmed Cell Death Protein 1 Inhibitor | Intimal Medial Thickness of Internal Carotid Artery

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Cancer Institute and Hospital, Chinese Academy...
The First Affiliated Hospital with Nanjing Medical University; Fujian Cancer... and other collaborators

Recruiting

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Esophageal Neoplasms

China
The Methodist Hospital Research Institute
Pfizer

Recruiting

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD-VACCINE)

Urothelial Carcinoma Bladder

United States
Peking Union Medical College Hospital

Recruiting

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Regorafenib

China
University of Nottingham

Completed

Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging (DITTO)

Infertility | Ovarian Aging | Diminished Ovarian Reserve (DOR) | Predicted Poor-responders

United Kingdom
Imperial College London

Not yet recruiting

A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs (PELICAN)

Neuroendocrine Tumors
Jiangsu Cancer Institute & Hospital

Recruiting

High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM (HaRyPOT)

Colorectal Liver Metastases

China
Janssen Research & Development, LLC

Active, not recruiting

An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants (OCTOPUS-1)

Hepatitis B, Chronic

France, Canada, Czechia, Italy, Taiwan, Turkey, Spain, United Kingdom
Xuzhou Medical University

Recruiting

A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom

Lung Squamous Cell Carcinoma

China
Brown University
Bristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...

Terminated

BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

Cervical Cancer

United States
Yonsei University

Withdrawn

Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)

Stage III NSCLC

Korea, Republic of
Shanghai Zhongshan Hospital

Recruiting

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Hepatocellular Carcinoma

China
Fudan University

Recruiting

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Gastric Cancer

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.; Shanghai Junshi Bioscience Co., Ltd.

Recruiting

PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC (Escape)

Esophageal Squamous Cell Carcinoma Abdominal Stage 0

China
Shanghai Zhongshan Hospital

Not yet recruiting

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Non-Small Cell Lung Cancer

China
Icahn School of Medicine at Mount Sinai

Recruiting

Pembrolizumab for Advanced NSCLC and PS 2-3

Non-Small Cell Lung Cancer (NSCLC)

United States
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Relapsed/Refractory Peripheral T-cell Lymphoma

China
Hospital JP Garrahan
Hospital Pereyra Rosell, Montevideo, Uruguay

Recruiting

Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. (LHGALOP2017)

Pediatric Hodgkin's Disease

Argentina
Li Xiao Wei

Not yet recruiting

HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) (HAI-TL)

Hepatocellular Carcinoma With PVTT

China
Roswell Park Cancer Institute

Withdrawn

Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

Malignant Solid Neoplasm | Lung Adenocarcinoma | Colorectal Carcinoma | Pancreatic Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | B-Cell Non-Hodgkin Lymphoma | Metastatic Pancreatic Carcinoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Pancreatic Carcinoma | Refractory T-Cell... and other conditions

United States
Chinese PLA General Hospital

Completed

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Ovarian Cancer

China
Jinling Hospital, China

Recruiting

Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC

Neoplasms | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Carcinoma | Antineoplastic Agents | Male Urogenital Diseases | Female Urogenital Diseases | Immune Checkpoint Inhibitors | Urogenital Diseases

China
Beijing Tongren Hospital

Unknown

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

NK/T Cell Lymphoma Nos

China
Vastra Gotaland Region

Recruiting

Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years (AML2012)

Pediatric Acute Myeloblastic Leukemia

Belgium, Denmark, Estonia, Finland, Hong Kong, Iceland, Netherlands, Norway, Sweden
Xijing Hospital

Recruiting

Preoperative Adjuvant SOX Plus PL-1 Antibody and FLOT Plus PD-1 Antibody for Locally Advanced dMMR Gastric Cancer

Gastric Cancer | Chemotherapeutic Toxicity | Immune-related Adverse Event

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Renal Cell Carcinoma | Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Solid Tumors

China
Fudan University
Anyang Tumor Hospital

Not yet recruiting

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Colon Cancer

China
Tongji Hospital
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma (CCGLC-008)

Hepatocellular Carcinoma Non-resectable

China
Shi Ming

Withdrawn

Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Esophageal Cancer

China
Sun Yat-sen University
Guangzhou No.12 People's Hospital; Kaiping Central Hospital

Withdrawn

HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC

Hepatocellular Carcinoma

China
Shi Ming

Suspended

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Intrahepatic Cholangiocarcinoma

China
Gradalis, Inc.

Completed

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

Melanoma | Malignant Melanoma | Melanoma Recurrent

United States
Sun Yat-sen University

Withdrawn

Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...
Tianjin Medical University General Hospital; Tianjin Chest Hospital

Completed

Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium

Delirium | Analgesia | NSCLC | Immunotherapy

China
Sichuan University

Recruiting

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

NSCLC | PD-1 Inhibitor | Stereotactic Body Radiotherapy | Low Dose Radiotherapy

China
Huiqiang Huang

Recruiting

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
Sun Yat-sen University

Recruiting

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | Immune Checkpoint Inhibitor

China
Amgen

Completed

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Belgium, Austria, Singapore, Australia, Netherlands, France, Japan, Taiwan, Canada
Amgen

Terminated

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United States, Sweden, Spain, United Kingdom, Australia, Denmark
Qilu Hospital of Shandong University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Unresectable Carcinoma

United States
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital... and other collaborators

Withdrawn

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Hepatocellular Carcinoma

China

Search clinical trials for: Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations